About Telix Pharmaceuticals
Telix Pharmaceuticals is a company based in Melbourne (Australia) founded in 2015. It operates as a Professional Services. Telix Pharmaceuticals has completed 9 acquisitions, including ANMI, ARTMS and ATLAB Pharma. Telix Pharmaceuticals offers products and services including Illuccix® and Gozellix®. Telix Pharmaceuticals operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, ImaginAb, Mariana Oncology and AdvanCell, among others.
- Headquarter Melbourne, Australia
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website telixpharma.com
- Social LinkedIn X Facebook YouTube
- Legal Name Telix Pharmaceuticals Limited
- Annual Revenue$835.42 M (USD)59.16as on Dec 31, 2025
- Net Profit-$7.39 M (USD)-122.14as on Dec 31, 2025
- EBITDA$40.99 M (USD)-32.01as on Dec 31, 2025
- Latest Funding Round$25M (USD), Post-IPO
Nov 2020
- Investors
- Investments & AcquisitionsANMI
& 8 more
Products & Services of Telix Pharmaceuticals
Telix Pharmaceuticals offers a comprehensive portfolio of products and services, including Illuccix® and Gozellix®.
Used for prostate cancer imaging in diagnostics.
Employed for prostate cancer imaging and diagnosis.
Apps and channels of Telix Pharmaceuticals
its YouTube channel Telix Pharma has 479 subscribers and 30 videos.
Videos from Telix Pharmaceuticals
The most watched videos on Telix Pharmaceuticals's YouTube channel, Telix Pharma (479 subscribers). Click a video to play it here.
More on Telix Pharma.
Funding Insights of Telix Pharmaceuticals
- Total Rounds 1
- Last Round Post-IPO — $25M
- First Round $25M
(Nov 2020)
- Investors Count 1
All 1 funding rounds of Telix Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $25M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Telix Pharmaceuticals
Telix Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include China Grand Pharmaceutical and Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finished formulations and APIs are manufactured for therapeutic categories. | 1995 | chinagrandpharm.com | Hong Kong, China |
Investor details for Telix Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Telix Pharmaceuticals
83 people are tracked at Telix Pharmaceuticals (39 in leadership, 15 in board & advisors, 29 in team).
| Name | Role | Group |
|---|---|---|
Namrata C. | Vp, Global Commercialization - Muskuloskeletal | Leadership |
Nabil Elshafeey | Medical Director Neuro And Rare Disease | Leadership |
Raphaël Ortiz | COO, EMEA | Leadership |
Jp Pal | Global Head Of Medtech, Digital & Ai/ml Marketing | Leadership |
Yannick Tremblay | Director, Engineering | Leadership |
Olga Pavlova | Director Global Regulatory Affairs | Leadership |
Darren Patti | COO, Americas | Leadership |
James Stonecypher | Chief Development Officer | Leadership |
Paul Schaffer | Chief Technology Officer | Leadership |
Craig Ulrick | Chief Information Officer | Leadership |
Darren Smith | Group Chief Financial Officer | Leadership |
Carl Cook | Vice President Clinical Operations | Leadership |
Lisa Yule | Associate Director, Regulatory Affairs - Biologics | Leadership |
Tom Fromm | Vice President Of Corporate Sales | Leadership |
Anthony Zinno | Vice President Of Commercial Operations | Leadership |
Charlotte Krenus | VP Operations - APAC | Leadership |
Sheila B. | Quality Director NA Operations | Leadership |
Edward P. | Director - Global Business Development, Telix Manufacturing Services (tms) | Leadership |
Rich Devaney | Area Vice President Of Sales | Leadership |
Akshay Chellappa | Vice President, Global Business Development | Leadership |
63 more people are available in the full profile.
Complete people profiles for Telix Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Telix Pharmaceuticals
Telix Pharmaceuticals is a publicly listed company on the ASX with ticker symbol TLX in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Nov 2017
- Listed onASX: TLX
- Listed entityTELIX PHARMACEUTICALS LIMITED
- Exchange sectorHealth technology
- ISINAU000000TLX2
- Share price16.30 AUD (+2.84% on the day) · 2026-10-12
- Market capitalisation5,394,236,705.00 AUD
- Price to earnings124.3
- EPS (diluted, trailing year)0.13 AUD
- Volume (last session)1,213,896
Financials of Telix Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.25B AUD | -11.1M AUD | 61.3M AUD |
| 2024 | 783.2M AUD | 49.9M AUD | 90.2M AUD |
| 2023 | 502.6M AUD | 5.2M AUD | 58.4M AUD |
| 2022 | 160.1M AUD | -104.1M AUD | -67.8M AUD |
| 2021 | 7.6M AUD | -80.5M AUD | -76.1M AUD |
Detailed financial statements for Telix Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Telix Pharmaceuticals
Telix Pharmaceuticals has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include ANMI, ARTMS and ATLAB Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Molecular imaging products and services are developed. | rls.bio | Miami, United States | 2018 | Sep 2024 | $230M | |
Radioisotope technologies and services are developed and provided by ARTMS. | artms.ca | Vancouver, Canada | 2013 | Mar 2024 | •••• | |
Preclinical and clinical services for therapeutic radiopharmaceuticals are offered. | isotherapeutics.com | Angleton, United States | 2005 | Feb 2024 | $8M | |
Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation | qsambio.com | Palm Beach, United States | 2004 | Feb 2024 | $123.1M | |
AI-driven clinical decision support for diagnosis and therapy planning | dedicaid.com | Vienna, Austria | 2017 | Apr 2023 | $1.2M | |
CRO focused on clinical research and tracer development services | optimaltracers.org | Sacramento, United States | 2013 | Nov 2022 | •••• | |
Monoclonal antibody conjugates are developed for cancer immunotherapy. | therapharm-deutschland.de | Giessen, Germany | 1999 | Nov 2020 | •••• | |
CDMO focused on synthesis of APIs | anmi.be | Herstal, Belgium | 2015 | Nov 2018 | $5.84M | |
Radio-antibodies for cancer treatment are developed by ATLAB Pharma. | atlab-pharma.com | Nantes, France | 2008 | Sep 2018 | •••• |
Complete acquisition details for Telix Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Telix Pharmaceuticals
12 dated milestones of Telix Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Telix Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ATLAB Pharma.
- Acquisition Acquires ANMI.
- Funding First funding round of $25.0M.
- Acquisition Acquires TheraPharm Deutschland.
- Acquisition Acquires Optimal Tracers.
- Acquisition Acquires Dedicaid.
- Acquisition Acquires QSAM Biosciences.
- Acquisition Acquires IsoTherapeutics.
- Acquisition Acquires ARTMS.
- Acquisition Acquires RLS Radiopharmacies.
Competitors of Telix Pharmaceuticals
Telix Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, ImaginAb, Mariana Oncology and AdvanCell, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| marianaoncology.com | 2020 | Watertown, United States | $250M | 41 | Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | |
| advancell.com.au | 2019 | Sydney, Australia | $129.42M | – | Radiopharmaceutical company developing targeted alpha therapies for cancer treatment | |
| acimmune.com | 2003 | Lausanne, Switzerland | $119.82M | – | Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases. | |
| lantheus.com | 2008 | Billerica, United States | – | 834 | Developer of diagnostic imaging agents and targeted therapeutics | |
| ariceum-therapeutics.com | 2021 | Berlin, Germany | $51.64M | – | Developer of drugs for systemic targeted radiation therapy to treat cancer |
Detailed competitors of Telix Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Telix Pharmaceuticals
The website of Telix Pharmaceuticals (telixpharma.com) receives about 31.7K visits a month and ranks #937,266 among all websites worldwide, #1,133 in Biotechnology and Pharmaceuticals.
- Monthly visits31.7K
▲ 13.4% vs previous month
- Unique visitors13.1K
per month
- Global rank#937,266
among all websites
- Category rank#1,133
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.4
- Average visit39 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Telix Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oraclinical.com | 100% | 8.4K | – | View details | |
| tonixpharma.com | 98% | 16.8K | #1,258,659 | View details | |
| mereobiopharma.com | 97% | 17K | #2,596,874 | View details | |
| contractpharma.com | 94% | 67.7K | #631,663 | View details | |
bioworld.com | bioworld.com | 94% | – | #311,180 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Telix Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Telix Pharmaceuticals
Complete news archive for Telix Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Telix Pharmaceuticals
10 companies that operate in the same segment as Telix Pharmaceuticals (Imaging Diagnostics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 190 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.17 M | – | 242 | |
Manufacturer of imaging and surgical products | 1919 | Tokyo, Tokyo, Japan | – | USD 6.49 B | 35,933 | |
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M | – | – | |
Planar X-ray radiology products for diagnostic imaging are supplied. | 2000 | Oxford, Oxfordshire, United Kingdom | USD 43.43 M | USD 1.04 M | 50 | |
Digital X-ray sources are developed by Nanox for cloud-based diagnostics. | 2004 | Jerusalem, Jerusalem District, Israel | USD 110.72 M | USD 13.02 M | 165 | |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | 2007 | Los Angeles, California, United States | USD 59.64 M | – | – | |
Portable wireless ultrasound systems are developed for medical imaging. | 2014 | Burnaby, British Columbia, Canada | USD 21.87 M | – | – | |
Portable MRI systems are manufactured for medical professionals. | 2014 | New York, New York, United States | – | USD 13.56 M | 111 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Telix Pharmaceuticals
Telix Pharmaceuticals was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Telix Pharmaceuticals is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Annual revenue of Telix Pharmaceuticals is $835.42M as on Dec 31, 2025.
Telix Pharmaceuticals is engaged in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, often referred to as theranostics. The companys extensive pipeline targets urologic oncology including prostate and kidney cancers, neuro-oncology such as glioma, musculoskeletal oncology like sarcoma, and bone marrow conditioning. Operations are supported by a robust global supply, manufacturing, and distribution network. Multiple clinical trials are conducted worldwide, with key products like Illuccix receiving regulatory approvals in various regions for prostate cancer imaging.
Telix Pharmaceuticals's top competitors include Advanced Accelerator Applications, ImaginAb and SOFIE.
Telix Pharmaceuticals offers Illuccix® and Gozellix®.
Yes, Telix Pharmaceuticals is publicly traded on ASX under the ticker symbol TLX.
Telix Pharmaceuticals has made 9 acquisitions, including ANMI, ARTMS, and ATLAB Pharma.
Telix Pharmaceuticals has 1 investor. Key investors include China Grand Pharmaceutical and Healthcare.
Telix Pharmaceuticals operates through Telix Pharmaceuticals Limited.